Status:
COMPLETED
Oral Versus Intravenous Tranexamic Acid
Lead Sponsor:
Hospital for Special Surgery, New York
Conditions:
Blood Loss
Blood Transfusion
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The goal of this randomized clinical control trial is to determine whether oral TXA dosing in THA/TKA result in more blood loss and more transfusions compared to IV TXA dosing in patients undergoing T...
Detailed Description
Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. The use of TXA in total hip arthroplasty (THA) and total knee arthroplasty (TKA) has r...
Eligibility Criteria
Inclusion
- Patients undergoing total hip arthroplasty (THA) through a posterior approach
- Patients undergoing total knee arthroplasty (TKA)
- Patients between 18-80 years of age
Exclusion
- Patients with \>80 years of age
- Patients with a BMI over 40
- Patients undergoing general anesthesia
- Patients with a history of major ipsilateral joint surgery
- Patients on pre-operative anticoagulation or anti-platelet drugs (other than aspirin)
- Patients with a history of bleeding disorders
- Patients with platelets less than 100/nl
- Patients with new-onset/active atrial fibrillation
- Patients with a history of myocardial infarction in the past year
- Patients with a history of a stroke in the past year
Key Trial Info
Start Date :
September 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04089865
Start Date
September 17 2019
End Date
November 10 2021
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital for Special Surgery
New York, New York, United States, 10021